Today: September 27, 2016, 9:01 am

Brazilian pharmaceutical drugs market forecast to be valued at US$41.3Bn in 2017
Brazilian Pharmaceutical Market 2014-2024 - a new market research report on 2014-03-19 00:45:01
By the end of 2017, the Brazilian drugs market is forecast to attain revenues of US$41.3 billion. The generics market sector is also forecast to represent the largest market sector in Brazil in terms of revenues. Over the next five years, Brazil will be the fastest expanding country in the world for pharmaceutical drugs market revenue with only China reporting a higher growth rate over this period.

The Brazil pharmaceuticals market is forecast to enter a period of further consolidation as Valeant, Merck and Takeda penetrate this market through acquisitions. The Brazilian government aims to retain its domestic generics industry despite further investment from multinationals.

The Brazilian pharma market will overtake every other except the US, China and Japan by 2020, according to expectations. The question is what strategies will get big pharma companies the best shares of that market. Sanofi is the market leader, but it has faced challenges. Though the generics market might seem like the simplest opportunity for sales growth in Brazil, there are also opportunities in patented pharmaceuticals, including biological drugs (biologics). But companies have to negotiate technology transfer arrangements.

Technology transfer is a flagship policy for the Brazilian government. It wants to expand the national pharma manufacturing base, increase expertise, and thus reduce the costs of importing medicines. This is increasingly a priority, because the government widens access to medicines. Pharma companies can get five years´ exclusivity, but in return they´ll have to sign up to transition their relevant technology over to Brazilian laboratories, reports indicate. The most important field for this kind of deal will be biologics (biological drugs). That´s what the government is interested in getting hold of, and we´ve seen in recent times the establishment of two conglomerates, BioNovis and Orygen, which are going to make biosimilars. At the moment Achê has biosimilars, but that field remains emergent in Brazil.

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600

# 518 Words
Related Articles
More From Finance
P2P lending platform Monexo partners with IDBI-Trusteeship [..]
For Immediate Release: 2nd September 2016 MUKESH BUBNA, CEO Monexo Fintech Pvt Limited P2P [..]
Day Trade to Win New September Class [..]
Sold Out? New Class Added – On September 6, 2016, is launching a brand new eight-week trading boot camp [..]
FTM (Forget The Market) Reopens 3 Shares [..]
Port Vila, Vanuatu, 28th July 2016 - Investment firm FTM today announced the reopening of three separate share options, projected [..]
Ex-Citibanker Launching Online P2P marketplace in India [..]
A study conducted by World Bank shows that MSMEs in India face an estimated credit gap of INR 20.9 trillion [..]
New Frontier Portfolios Top Morningstar Rankings
New Frontier’s global strategic portfolios topped the Global Balanced Strategic/All-Inclusive category of the latest Morningstar ETF [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.